Cessatech AS
8GN
Company Profile
Business description
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
Contact
Strandvejen 60
HellerupDK- 2900
DNKT: +45 93872309
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Undervalued REIT receives offer from PE firm
Our analysts’ view on the value of the unsolicited offer.
stocks
Apple: With launch of foldable iPhone duo things look twice as nice
We’ve raised our fair value estimate of Apple stock.
stocks
What did Morningstar subscribers buy and sell during August?
Earnings season fuels trading activity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.20 | 10.80 | 0.12% |
| CAC 40 | 8,116.76 | 0.00 | 0.00% |
| DAX 40 | 25,361.15 | 215.30 | -0.84% |
| Dow JONES (US) | 52,064.10 | 316.56 | -0.60% |
| FTSE 100 | 10,608.92 | 61.14 | -0.57% |
| HKSE | 24,830.02 | 124.45 | -0.50% |
| NASDAQ | 26,081.72 | 171.62 | -0.65% |
| Nikkei 225 | 63,939.26 | 1,331.69 | -2.04% |
| NZX 50 Index | 13,580.33 | 130.68 | -0.95% |
| S&P 500 | 7,591.70 | 44.66 | -0.58% |
| S&P/ASX 200 | 8,738.40 | 20.50 | 0.24% |
| SSE Composite Index | 3,891.31 | 43.09 | -1.10% |